Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012, 380: 581-590.
Article
CAS
PubMed
Google Scholar
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376: 1670-1681.
Article
CAS
PubMed
Google Scholar
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, op Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 2012 (33): 1635-1701.
Google Scholar
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011, 32: 1769-1818.
Article
PubMed
Google Scholar
Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E: 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013, 29: 151-167. 10.1016/j.cjca.2012.11.032.
Article
PubMed
Google Scholar
Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, et al: ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014, 129: S1-S45. 10.1161/01.cir.0000437738.63853.7a.
Article
PubMed
Google Scholar
Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R: Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010, 376: 1658-1669.
Article
PubMed
Google Scholar
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, et al: Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation. 2013, 127: 143-152. 10.1161/CIR.0b013e318282ab8f.
Article
PubMed
Google Scholar
Jones PH, Nair R, Thakker KM: Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012, 1: e001800-
Article
PubMed
PubMed Central
Google Scholar
Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Masso-Gonzalez EL, Jimenez FJ, Perk J, Steg PG, De Backer G, Rodríguez-Artalejo F: Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011, 32: 2143-2152. 10.1093/eurheartj/ehr080.
Article
PubMed
PubMed Central
Google Scholar
Gitt AK, Junger C, Smolka W, Bestehorn K: Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol. 2010, 99: 723-733. 10.1007/s00392-010-0177-z.
Article
PubMed
PubMed Central
Google Scholar
Hermans MP, Castro CM, Strandberg T, Ferrieres J, Feely J, Elisaf M, Michel G, Sansoy V: Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin. 2010, 26: 445-454. 10.1185/03007990903500565.
Article
CAS
PubMed
Google Scholar
Kotseva K, Wood D, De Backer G, De Backer D, Pyorala K, Keil U: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009, 373: 929-940. 10.1016/S0140-6736(09)60330-5.
Article
PubMed
Google Scholar
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011, 365: 2255-2267.
Article
PubMed
Google Scholar
Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC, Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010, 362: 1563-1574.
Article
PubMed
Google Scholar
Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003, 100: 928-933. 10.1073/pnas.0335507100.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chan JC, Piper DE, Cao Q, Liu D, King C, Wang W, Tang J, Liu Q, Higbee J, Xia Z, Di Y, Shetterly S, Arimura Z, Salomonis H, Romanow WG, Thibault ST, Zhang R, Cao P, Yang XP, Yu T, Lu M, Retter MW, Kwon G, Henne K, Pan O, Tsai MM, Fuchslocher B, Yang E, Zhou L, Lee KJ, et al: A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009, 106: 9820-9825. 10.1073/pnas.0903849106.
Article
CAS
PubMed
PubMed Central
Google Scholar
Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ: High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res. 2010, 51: 2714-2721. 10.1194/jlr.M008144.
Article
CAS
PubMed
PubMed Central
Google Scholar
Farnier M: PCSK9 inhibitors. Curr Opin Lipidol. 2013, 24: 251-258. 10.1097/MOL.0b013e3283613a3d.
Article
CAS
PubMed
Google Scholar
Cariou B, Le May C, Costet P: Clinical aspects of PCSK9. Atherosclerosis. 2011, 216: 258-265. 10.1016/j.atherosclerosis.2011.04.018.
Article
CAS
PubMed
Google Scholar
Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, Wu R, Pordy R: Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012, 380: 29-36. 10.1016/S0140-6736(12)60771-5.
Article
CAS
PubMed
Google Scholar
McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012, 59: 2344-2353. 10.1016/j.jacc.2012.03.007.
Article
CAS
PubMed
Google Scholar
Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA: Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012, 367: 1891-1900. 10.1056/NEJMoa1201832.
Article
CAS
PubMed
Google Scholar
Siddiqui O, Hung HM, O’Neill R: MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat. 2009, 19: 227-246. 10.1080/10543400802609797.
Article
PubMed
Google Scholar
National Research Council: The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education. 2010, Washington, DC: The National Academies Press
Google Scholar
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JA, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG: Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. Am Heart J. ᅟ, ᅟ: ᅟ-in press
Google Scholar
Wang KF, Chang CC, Wang KL, Wu CH, Chen LC, Lu TM, Lin SJ, Chiang CE: Determinants of low-density lipoprotein cholesterol goal attainment: Insights from the CEPHEUS Pan-Asian Survey. J Chin Med Assoc. 2014, 77: 61-67. 10.1016/j.jcma.2013.10.013.
Article
CAS
PubMed
Google Scholar
Keating AJ, Campbell KB, Guyton JR: Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013, 47: 398-404. 10.1345/aph.1R509.
Article
PubMed
Google Scholar
Xanthopoulou I, Davlouros P, Siahos S, Perperis A, Zaharioglou E, Alexopoulos D: First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. Lipids Health Dis. 2013, 12: 170-10.1186/1476-511X-12-170.
Article
PubMed
PubMed Central
Google Scholar
Karalis DG, Victor B, Ahedor L, Liu L: Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol. 2012, 2012: 861924-
Article
PubMed
PubMed Central
Google Scholar
Arca M, Pigna G: Treating statin-intolerant patients. Diabetes Metab Syndr Obes. 2011, 4: 155-166.
Article
PubMed
PubMed Central
Google Scholar
Jackevicius CA, Mamdani M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002, 288: 462-467. 10.1001/jama.288.4.462.
Article
PubMed
Google Scholar
Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K: Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease. J Clin Lipidol. 2014, 8: 107-116. 10.1016/j.jacl.2013.09.009.
Article
PubMed
Google Scholar
Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM: Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012, 223: 251-261. 10.1016/j.atherosclerosis.2012.02.016.
Article
CAS
PubMed
Google Scholar
Pordy R, Lecorps G, Bessac L, Sasiela WJ, Ginsberg HN: Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic dosing in phase 3 studies. J Clin Lipidol. 2013, 7: 279-
Article
Google Scholar
Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R: Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007, 370: 1829-1839.
Article
PubMed
Google Scholar
Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989, 320: 904-910. 10.1056/NEJM198904063201405.
Article
CAS
PubMed
Google Scholar
Goldstein LB: Low LDL cholesterol, statins, and brain hemorrhage: should we worry?. Neurology. 2007, 68: 719-720. 10.1212/01.wnl.0000258538.06950.a1.
Article
PubMed
Google Scholar
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.
Article
PubMed
Google Scholar
Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GB, McPherson R, Francis GA, Poirier P, Lau DC, Grover S, Genest J, Carpentier AC, Dufour R, Gupta M, Ward R, Leiter LA, Lonn E, Ng DS, Pearson GJ, Yates GM, Stone JA, Ur E: Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel. Can J Cardiol. 2014, 30: 377-380. 10.1016/j.cjca.2014.01.009.
Article
PubMed
Google Scholar